Trials / Completed
CompletedNCT03627065
A Study of INCB050465 in Primary Sjögren's Syndrome
An Open-Label Phase 2 Study of INCB050465 in Participants With Primary Sjögren's Syndrome
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the impact of parsaclisib on the signs and symptoms of Sjögren's syndrome (SS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Parsaclisib | Parsaclisib administered orally once daily at the protocol-defined dose. |
Timeline
- Start date
- 2019-02-28
- Primary completion
- 2019-12-07
- Completion
- 2020-01-02
- First posted
- 2018-08-13
- Last updated
- 2021-08-13
- Results posted
- 2021-03-24
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03627065. Inclusion in this directory is not an endorsement.